WDVAX / Dana-Farber Cancer Institute - LARVOL DELTA

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1 | N=23 | Completed | Sponsor: Dana-Farber Cancer Institute | Active, not recruiting ➔ Completed

Trial completion • Melanoma • Oncology • Solid Tumor

First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Metastatic Melanoma Patients. (PubMed, Cancer Immunol Res) - "This materials system served as a physical antigen-presenting structure for which dendritic cells and other immune-stimulating cells are recruited and activated (WDVAX). In this first clinical trial of a macroscale biomaterial-based vaccine, WDVAX treatment was found to be feasible and induced immune activation in melanoma patients."

Journal • P1 data • Melanoma • Oncology • Solid Tumor • CSF2

Heterologous prime-boost immunization of two-component vaccine candidate PWDVax protected pigs against F18 enterotoxigenic Escherichia coli post-weaning diarrhea. (PubMed, Infect Immun) - "This makes PWDVax potentially an effective vaccine to protect against PWD, particularly the current F18 ETEC-associated severe PWD outbreaks in the United States. Additionally, the two-component vaccine and heterologous prime-boost immunization strategy may also facilitate the development of effective neonatal vaccines for humans."

Journal

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Aug 2022 ➔ Dec 2022 | Trial primary completion date: Aug 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jan 2022 ➔ Aug 2022 | Trial primary completion date: Jan 2022 ➔ Aug 2022

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Trial completion date: Jun 2021 ➔ Jan 2022; Trial primary completion date: Jun 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Trial completion date: Jun 2020 ➔ Jun 2021; Trial primary completion date: Jun 2020 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: Jun 2019 ➔ Jun 2020

Clinical • Trial primary completion date

Dendritic Cell Activating Scaffold in Melanoma (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed